Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.